Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Lupin Ltd has introduced Ipratropium Bromide nasal spray in the US, available in 0.03% and 0.06% strengths. These sprays, ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.

Ipratropium bromide nasal solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with ...

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies Provided by GlobeNewswire Jul 3, 2025, 12:00:00 AM ...

Mumbai: Global pharma major Lupin Limited has launched Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Global Animal Health Market is expected to grow at a rate of 8-9% by 2029. Growing awareness of animal health products, ...

The OBT-Boehringer partnership began in 2013 and has expanded through subsequent agreements in 2020 and 2022 to include additional programs. The collaboration has yielded multiple development-stage ...